Skip to content

Author

In-Jin Jang

We have 2 of 31 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Safety, pharmacodynamics and pharmacokinetics of a novel JAK1-selective inhibitor, IN-115314, in healthy participants: A first-in-human study.

AIMS Selective JAK1 inhibition can control inflammation in immune-mediated diseases with reduced haematological toxicity. IN-115314, a selective JAK1 inhibitor, was evaluated in a first-in-human, randomized, double-blind, placebo-controlled study in healthy participants for safety, pharmacokinetics (PK) and pharmacodyn...

K. Huh, Jaegu Kang, Haerim Jang et al. · 0 citations
Open access Aug 2026

Prospective Study of Targeted Busulfan-Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases.

Pharmacokinetic-guided busulfan-fludarabine conditioning achieved reliable engraftment with acceptable toxicity in children with GRDs, supporting its use as a safe, effective HSCT conditioning strategy in vulnerable populations.

B. Kim, K. Hong, J. Choi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.